JP2023549837A5 - - Google Patents
Info
- Publication number
- JP2023549837A5 JP2023549837A5 JP2023528580A JP2023528580A JP2023549837A5 JP 2023549837 A5 JP2023549837 A5 JP 2023549837A5 JP 2023528580 A JP2023528580 A JP 2023528580A JP 2023528580 A JP2023528580 A JP 2023528580A JP 2023549837 A5 JP2023549837 A5 JP 2023549837A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- pharmaceutical composition
- hyaluronidase
- composition according
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115002P | 2020-11-17 | 2020-11-17 | |
| US63/115,002 | 2020-11-17 | ||
| PCT/EP2021/082031 WO2022106487A1 (en) | 2020-11-17 | 2021-11-17 | Treatment or prevention of a disease or disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549837A JP2023549837A (ja) | 2023-11-29 |
| JP2023549837A5 true JP2023549837A5 (cg-RX-API-DMAC10.html) | 2024-11-25 |
Family
ID=78806517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528580A Pending JP2023549837A (ja) | 2020-11-17 | 2021-11-17 | 疾患又は障害の治療又は予防 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230405094A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4247333A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023549837A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230110763A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116437901A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021382120A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3196877A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL302860A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2023005760A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022106487A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120813342A (zh) * | 2023-02-20 | 2025-10-17 | 林迪生物科学公司 | 透明质酸酶颗粒、包含其的组合物及其制备和使用方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2330213A1 (en) | 2003-03-05 | 2011-06-08 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| PT3366278T (pt) * | 2006-06-23 | 2024-10-21 | Janssen Sciences Ireland Unlimited Co | Suspensões aquosas de tmc278 |
| CN101970650B (zh) * | 2008-03-06 | 2017-07-25 | 哈洛齐梅公司 | 可溶性透明质酸酶的大规模生产 |
| TWI489994B (zh) * | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| US20090311237A1 (en) * | 2008-04-14 | 2009-12-17 | Frost Gregory I | Combination therapy using a soluble hyaluronidase and a bisphosphonate |
| PT2477603E (pt) * | 2009-09-17 | 2016-06-16 | Baxalta Inc | Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização |
| HRP20201241T1 (hr) * | 2011-04-15 | 2020-11-27 | Janssen Pharmaceutica N.V. | Nanosuspenzije lijeka osušene zamrzavanjem |
| JP7560946B2 (ja) * | 2016-11-10 | 2024-10-03 | トランスレイト バイオ， インコーポレイテッド | メッセンジャーｒｎａの皮下送達 |
-
2021
- 2021-11-17 MX MX2023005760A patent/MX2023005760A/es unknown
- 2021-11-17 WO PCT/EP2021/082031 patent/WO2022106487A1/en not_active Ceased
- 2021-11-17 JP JP2023528580A patent/JP2023549837A/ja active Pending
- 2021-11-17 CN CN202180076908.9A patent/CN116437901A/zh active Pending
- 2021-11-17 AU AU2021382120A patent/AU2021382120A1/en not_active Abandoned
- 2021-11-17 CA CA3196877A patent/CA3196877A1/en active Pending
- 2021-11-17 KR KR1020237020276A patent/KR20230110763A/ko not_active Withdrawn
- 2021-11-17 EP EP21815467.2A patent/EP4247333A1/en active Pending
- 2021-11-17 US US18/037,218 patent/US20230405094A1/en active Pending
- 2021-11-17 IL IL302860A patent/IL302860A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11248000B2 (en) | Quinazoline and indole compounds to treat medical disorders | |
| ES3040193T3 (en) | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | |
| US11001600B2 (en) | Disubstituted compounds for treatment of medical disorders | |
| US10906887B2 (en) | Amino compounds for treatment of immune and inflammatory disorders | |
| US20210115034A1 (en) | Amide compounds for treatment of immune and inflammatory disorders | |
| US10385097B2 (en) | Ether compounds for treatment of medical disorders | |
| ES2555279T3 (es) | Neuroprotección en enfermedades desmielinizantes | |
| TWI721008B (zh) | 具拮抗ｐｄｌ１功能的適體分子於癌症治療之應用 | |
| TW201718611A (zh) | 用於治療醫學病症之膦酸酯化合物 | |
| ES2712688T3 (es) | Métodos y composiciones para el tratamiento de la esclerosis múltiple y trastornos asociados | |
| WO2017035352A1 (en) | Carbamate, ester, and ketone compounds for treatment of medical disorders | |
| JP2013507131A5 (cg-RX-API-DMAC10.html) | ||
| JP2022526763A5 (cg-RX-API-DMAC10.html) | ||
| TW201429988A (zh) | 介白素－６抗體及其用途 | |
| CN105188710A (zh) | 包含缓冲的氨基烷基氨基葡糖苷磷酸酯衍生物的组合物及其用于增强免疫应答的用途 | |
| Jallow et al. | Versatility of LNPs across different administration routes for targeted RNA delivery | |
| Ye et al. | Macrophages as nanocarriers for drug delivery: novel therapeutics for central nervous system diseases | |
| JP2020037562A (ja) | 炎症性関節疾患の治療方法 | |
| JPWO2004035779A1 (ja) | ウイルスエンベロープを用いた生体分子の導入方法ならびにそのための組成物およびシステム | |
| Chen et al. | A comprehensive analysis of biopharmaceutical products listed in the FDA’s Purple Book | |
| JP2023546923A5 (cg-RX-API-DMAC10.html) | ||
| JP6820841B2 (ja) | ペグ化インターフェロンのための投薬計画 | |
| Qiu et al. | Pulmonary delivery of Messenger RNA (mRNA) therapeutics for respiratory diseases | |
| JP2770911B2 (ja) | 抗ウイルス医薬組成物 | |
| CN116437901A (zh) | 疾病或病症的治疗或预防 |